<DOC>
	<DOCNO>NCT00885885</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination Panitumumab FOLFOX 4 Chemotherapy Panitumumab FOLFIRI Chemotherapy Subjects Wild- Type KRAS Colorectal Cancer liver-only Metastases .</brief_summary>
	<brief_title>Safety Efficacy Study FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab Subjects WT KRAS Colorectal Cancer Liver-only Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Man woman &gt; 18 year &lt; 75 age Competent comprehend , sign , date IECapproved inform consent form Histologically confirm adenocarcinoma colon rectum Wild Type KRAS status Metastatic colorectal carcinoma exclusively affect liver , compliant one follow criterion 1 . Number liver metastasis ≥ 4 . 2 . Size one liver metastasis &gt; 10 cm diameter . 3 . Liver metastases technically resectable . At least 1 unidimensionally measurable lesion Patients follow characteristic include : 1 . Recurrence adjuvant treatment 5fluorouracil/folinic acid capecitabine +/ radiotherapy diseasefree interval &gt; 6 month completion ; oxaliplatin contain adjuvant treatment diseasefree interval &gt; 12 month 2 . Recurrence surgical treatment and/or radiotherapy adjuvant systemic treatment . 3 . De novo diagnosis disease . Patients simultaneous liver metastasis eligible , primary tumor resect least 1 month prior chemotherapy . Prior radiotherapy acceptable . Patients deem major contraindication liver surgery general health perspective . Karnofsky performance status ≥ 70 % Adequate bone marrow function : neutrophil ≥ 1.5 x109/ L ; platelet ≥ 100 x109/ L ; hemoglobin ≥ 9g/ dL Hepatic metabolic function follow : Total bilirubin count ≤ 1.5 x ULN increase 25 % within last 4 week ; ALAT ASAT &lt; 5 x ULN ; Renal function , calculate creatinine clearance 24 hour creatinine clearance ≥ 50 mL/ min . Magnesium &gt; LLN Prior antiEGFr antibody therapy ( eg , cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( eg , erlotinib ) .Subjects experienced infusion reaction first dose antiEGFR therapy ( cetuximab ) may participate clinical trial . Surgery ( include diagnostic biopsy ) and/or radiotherapy 4 week prior inclusion study . Metastasis site liver , include extrahepatic lymph node . Prior malignant tumor last 5 year , except history basal cell carcinoma skin preinvasive carcinoma skin . Systemic chemotherapy , hormonal therapy , immunotherapy experimental approve proteins/antibodies ( eg , bevacizumab ) ≤ 30 day inclusion Unresolved toxicities prior systemic therapy , opinion investigator , qualify patient inclusion Significant cardiovascular disease include unstable angina myocardial infarction within 6 month initiate study treatment history ventricular arrhythmia History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest CT scan Treatment systemic infection within 14 day initiate study treatment Active inflammatory bowel disease bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) History Gilbert 's syndrome dihydropyrimidine deficiency History medical condition may increase risk associate study participation may interfere interpretation study result Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection subject allergic ingredient study medication Staphylococcus protein A Any comorbid disease would increase risk toxicity Any kind disorder compromise ability subject give write informed consent and/or comply study procedures Any investigational agent within 30 day enrolment Must major surgical procedure within 28 day randomization Subject pregnant breast feed Woman man childbearing potential consenting use adequate contraceptive precaution i.e . double barrier contraceptive method ( eg diaphragm plus condom ) , abstinence course study 6 month last study drug administration woman , 1 month men Subject unwilling unable comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>FOLFOX-4</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>